Senores Pharma Shares Fall 6% Despite Strong Q3 Performance, Margin Expansion

• Senores Pharmaceuticals reported an 88% jump in net profit to ₹32 crore and a 69.4% revenue surge to ₹174.5 crore in Q3 FY26.
• EBITDA more than doubled to ₹54 crore, with margins expanding to 31% from 25%, driven by operating leverage and improved product mix.
• The company strengthened its regulated markets pipeline with 46 approved ANDAs and 22 more under development, ensuring long-term growth visibility.
• Emerging markets achieved highest-ever quarterly revenue and EBITDA, with margins expanding to 13% and the segment turning cash flow positive.
• Senores completed the first phase of Apnar Pharmaceuticals acquisition (75% stake), with three ANDAs from Apnar set for launch in Q4FY26.

Why It Matters: Senores Pharma saw its shares drop despite robust Q3 results, strong growth, and strategic acquisitions.